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Abstract
Pancreatic ductal adenocarcinoma (PDAC) commonly contains a mutation in K-RasG12D and is characterized by a
desmoplastic reaction composed of deregulated, proliferating cells embedded in an abnormal extracellular matrix
(ECM). Our previous observations imply that inhibiting the mitogen-activated protein kinase (MAPK)–extracellular
signal-regulated kinase (ERK2) kinase signal pathway reverses amatrix metalloproteinase 1–specific invasive pheno-
type. Here, we investigated the specific genes downstream of MAPK-ERK2 responsible for the hyperproliferative
abilities of human and murine primary ductal epithelial cells (PDCs) within an ECM. Compared with control, DNA
synthesis and total cell proliferation was significantly increased in human PDCs harboring the PDAC common p53,
Rb/p16INK4a, and K-RasG12D mutations. Both of these effects were readily reversed following small-molecule inhi-
bition or lentiviral silencing of ERK2. Microarray analysis of PDCs in three-dimensional (3D) culture revealed a
unique, MAPK-influenced gene signature downstream of K-RasG12D. Unbiased hierarchical analysis permitted fil-
tration of tissue inhibitor of matrix metalloproteinase 1 (TIMP1). Pancreatic cells isolated from Pdx1-Cre;LSL-
KrasG12D/+–mutated mice exhibit increased TIMP1 RNA transcription compared to wild-type littermate controls.
Analyses of both 3D, in vitro human K-RasG12D PDCs and data mining of publicly annotated human pancreatic data
sets correlatively indicate increased levels of TIMP1 RNA. While silencing TIMP1 did not significantly effect PDC
proliferation, exogenous addition of human recombinant TIMP1 significantly increased proliferation but only in
transformed K-RasG12D PDCs in 3D. Overall, TIMP1 is an upregulated gene product and a proliferative inducer of
K-RasG12D–mutated PDCs through the ERK2 signaling pathway.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is derived from an initial,
injury-induced, or K-Ras–induced acinar-to-ductal metaplasia followed
by a stepwise pancreatic intraepithelial neoplastic progression (PanIN)
of the cells lining the ducts of the exocrine pancreas [1,2]. PDAC is
characterized by a highly proliferative, desmoplastic microenvironment
consisting of epithelial and stromal hyperplasia and abnormal extra-
cellular matrix (ECM) assembly [3]. More than 90% of PDACs harbor
a K-RasG12D mutation that inhibits GTPase functionality and initiates
constitutively active downstream kinase signaling [4,5]. PDAC acti-
vates a variety of downstream signaling pathways that contribute to
cancer growth, motility, invasion, and metastasis [6]. Recently, we de-
scribed a distinct K-RasG12D–mediated invasive signaling pathway in
cultured pancreatic ductal epithelial cells (PDCs) that specifically in-
volves the mitogen-activated protein kinase (MAPK)–extracellular
signal-regulated kinase (ERK2) signaling pathway. Specifically, activa-
tion of the ERK2 isoform results in the up-regulation of a variety of
oncogenic genes, including matrix metalloproteinases (MMPs) and
tissue inhibitor of matrix metalloproteinases (TIMPs), which is evident
only when cells are cultured in three-dimensional (3D) ECM-derived
hydrogels [7].
TIMPs are 22- to 28-kDa protease inhibitory proteins that regu-
late the proteolytic activity of MMPs by sterically binding to and in-
hibiting activation of their catalytic zinc moiety [8]. In normal tissue,
a proper balance is maintained between TIMPs and MMPs, which
enables controlled cellular remodeling of the ECM [9]. Disruption of
this balance leads to numerous pathologies, including inflammatory
arthritis, tumor growth, and metastasis [9,10]. The conserved TIMP
family is currently comprised of four subtypes (TIMP1, TIMP2,
TIMP3, and TIMP4) all sharing several gene sequence homologies
as well as structural protein similarities. Specifically, the N-terminal
region is capable of binding to the catalytic zinc site of MMPs, a side
chain that inserts into specific MMP clefts, while the C-terminal
region enables receptor-ligand signaling [11]. Interestingly, only TIMP1
resides on the X chromosome and is the only member to have its first
exon transcribed but not translated [12]. Some activated transcription
factors, such as Ets family members, bind to exon/intron 1 upstream of
the translational start site and regulate TIMP1 expression. Increased
TIMP1 expression is observed in fetal ductal morphogenesis and
growth as well as during active epithelial proliferation of pubertal mam-
mary ducts. Conversely, homozygous TIMP1−/− knockout mice exhibit
alterations of the terminal ducts and their basement membrane [13].
PDAC mouse models along with human biopsies, serum, and
stroma exhibit increased gene expression and secretion of TIMP1,
which may be due to elevated levels of transforming growth factor–β,
interleukin, and leukemia inhibitory factor [12,14]. TIMP1 expres-
sion levels have been used diagnostically as indicators of poor outcome
prognosis in both mammary and pancreatic carcinoma [15,16]. How-
ever, it is unclear whether TIMP1 up-regulation is a secondary response
to a neoplastic increase in MMP expression or if TIMP1 itself harbors
pro-tumorigenic, anti-apoptotic features [5,9,17–19,25]. While a major-
ity ofTIMP1 expression studies have been carried out in two-dimensional
(2D) in vitro environments, recent evidence suggests that its tumorigenic
properties are only evident in 3D culture [18,20–22].
Our results indicate that only constitutively active K-RasG12D–mutated
PDCs exhibit significant TIMP1 RNA and protein increases through the
MAPK-ERK2 pathway. Further, elevated levels of TIMP1 expression are
seen in human in vitromodels incorporating a 3D ECM as well as in vivo
K-RasG12D mouse models. Lastly, the exogenous addition of human re-
combinant TIMP1 (rTIMP1) sufficiently increases cellular aggregate
growth and DNA synthesis but only in 3D E6/E7/Ras PDCs.
Materials and Methods
Human Cell Lines
The isogenic set of immortalized primary human PDCs was a gen-
erous gift from Dr Michel Ouellette (University of Nebraska) [23].
All populations were maintained in conventional 2D cultures in T-75
flasks in a humidified incubator (95% air/5% CO2) at 37°C and cul-
tured in a pancreatic-specific growth medium [complete pancreatic
medium (CPM)]: four parts low-glucose Dulbecco’s modified Eagle’s
medium (Cellgro, Manassas, VA) to one part M3 base culture medium
(INCELL, San Antonio, TX) supplemented with 5% FBS + 1%
penicillin-streptomycin. Cells were passaged every 48 hours by 0.05%
trypsin detachment over 5 minutes, as previously described [7].
Murine Pancreatic Ductal Cell Isolation
Single-cell suspensions of primary isolates from the mouse pancreas
were prepared as described previously [24,25]. Briefly, a mixed cell
population was resuspended and divided into several fractions each
containing 106 cells with one fraction kept as a pre-sorting sample.
Fluorescein-labeled Dolichos Biflorus Agglutinin (DBA) lectin or
biotin-labeled DBA (Vector Laboratories, Inc, Burlingame, CA), re-
spectively, was added and the cells were washed and pelleted. Anti–
fluorescein isothiocyanate or streptavidin-coated nanobeads (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany), respectively, were added
and incubated before magnetic separation was performed using magnetic-
activated cell sorting (MACS) columns (Miltenyi Biotec GmbH), accord-
ing to the manufacturer’s protocol. RNA from each of the three fractions
[DBA positive (+), DBA negative (−), and pre-sorting] was isolated using
the RNAqueous-Micro Kit (Ambion, Inc, Austin, TX).
3D Cell Culture Assays
3D cultures of PDCs were established as previously published [7].
Briefly, 200 μl of growth factor reduced (GFR) Matrigel (BD Bio-
sciences, San Jose, CA, #354230) was spread within a 12-well tissue
culture plate at a concentration of 10.5 mg/ml and incubated at 37°C
for 30 minutes. The polymerized matrix had an elastic modulus of
approximately 5 to 8 kPa as determined by rheometry (Bohlin CS,
Lund, Sweden). The elastic modulus of the native (healthy) human
pancreas is ∼500 Pa, which is similar to that of normal breast tissue
(∼600 Pa) and liver (640 Pa), as determined by atomic force micros-
copy and rheometry [7]. To further decrease the elastic modulus of our
matrix construct to levels approximating modulus of native pancreas,
another 50 μl of GFR Matrigel was added to the center of the already
coated well and solidified for another 30 minutes at 37°C to obtain an
average elastic modulus of 480 ± 63 Pa at the center of each well. Cells
growing in log phase were trypsinized and resuspended at a concentration
of 10,000 cells/ml in culture medium, which consisted of a 50:50 mix-
ture of 3D media (Dulbecco’s modified Eagle’s medium/F12, 2% horse
serum, 100 μg/ml hydrocortisone, 1 μg/ml cholera toxin, 10 μg/ml
insulin, and 1% penicillin-streptomycin) and CPM (see above), which
was then supplemented with 2% vol/vol of GFR Matrigel. Two milli-
liters of this cell suspension was added to each well. PDCs were cultured
from 1 to 8 days with a medium change every fourth day.
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Cell Proliferation Analysis
DNA synthesis of PDCs cultured in 2D and 3D cultures was mea-
sured using the Invitrogen Click-iT EdU Assay (C10337). Briefly,
0.2 × 106 PDCs were plated the night before analysis in 2D supplemen-
ted with CPM or 3D supplemented with CPM and 2% GFR Matrigel
in a 12-well plate. A 1× EdU solution was added to each well for
3 hours, the medium was removed, and the cells were fixed with
3.7% formaldehyde in phosphate-buffered saline (PBS) for 15 minutes.
The wells were rinsed two times with 3% BSA in PBS and permeabi-
lized with 0.5% Triton X-100 in PBS for 20 minutes at room temper-
ature. A 1× Click-iT reaction cocktail was prepared by sequential
addition of reaction buffer, copper sulfate (CuSO4), Alexa Fluor 488
azide, and reaction buffer additive, as per the manufacturer’s instruc-
tions. Following removal of the permeabilization solution, the wells
Figure 1. K-RasG12D–mutated PDCs reveal increased proliferation in 3D. (A) Schematic of the transduction of primary human PDCs with
human telomerase (hTERT), the human papillomavirus proteins E6 and E7, and a K-RasG12D mutation to yield three separate clone lines
with a common genetic background. (B) Each clone was cultured either in 2D (left panels, ×20) or 3D ECM (right panels, ×10) for 72 hours
and evaluated for proliferative and morphologic characteristics. Scale bars, 50 μm. (C) Total cell numbers for each individual clone was
quantified after 72 hours in 3D culture at 12-hour intervals. At each time point, cell numbers were determined as the average count of five
individual fields of three separate cultures of each individual clone. Data are presented asmeans± SEM. *P< .05, **P< .01. (D) Two-way
ANOVA through Tukey B Test for Contrasts on Ordered Means of each clone confirms significant differences in proliferation in 3D at
48 hours (left graph) and 72 hours (right graph). (E) The total number of cells per aggregate was quantified for each PDC clone after 72 hours
in 3D culture. Ten separate aggregates of each clone from three different experiments were averaged. *P < .05. Data are presented as
means ± SEM.
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were washed two times for 5 minutes each with 3% BSA in PBS and
500 μl of the Click-iT reaction cocktail was added to each well and
incubated for 30 minutes at room temperature in the dark. Afterward,
the wells were washed again with 3% BSA in PBS, and the cells were
counterstained with a 1:2000 dilution of 4′,6-diamidino-2-phenylindole
(DAPI) in PBS for 40minutes at room temperature. The wells were finally
washed two times with PBS and five random fields were imaged using a
Nikon TE-2000 fluorescence microscope. A first image was taken using
the DAPI filter cube followed by EdU imaging using a 488/520 nm filter
cube. Each individual image was pseudocolored with blue or green ImageJ
filters to provide the correlative wavelength observed for each fluores-
cently tagged cell. These images were then analyzed in ImageJ using the
automatic counting subroutine macro to filter cells not proliferating
(blue filter only) to those proliferating (blue + green filters combined).
The EdU-positive cells were divided by the number of DAPI-positive
cells to obtain the fraction undergoing active DNA synthesis.
Pharmacologic Inhibition Experiments
The MAPK/ERK kinase (MEK) inhibitor bis[amino[(2-aminophenyl)
thio]methylene]butane-dinitrile (UO126; Calbiochem, Gibbstown,
NJ) was obtained from Invitrogen (Carlsbad, CA), dissolved in DMSO
stored at −20°C, and used at final concentrations of 5 and 10 μM to
verify concentration dependence. The specific ERK2 inhibitor 3-
(2-aminoethyl)-5-((4-ethoxyphenyl)methylene)-2,4-thiazolidine hydro-
xychloride (AEMT; Calbiochem, 328006) was stored at −20°C and
used at a 20 μM final concentration.
RNA Isolation
RNA was isolated from 3D cultures of human PDCs grown in
CPM on GFR Matrigel by trypsinization as previously described
[7]. Briefly, 5 ml of freshly thawed 0.05% trypsin, supplemented
with a 1:100 dilution of a phosphatase and protease inhibitor cocktail
(Thermo, Rockford, IL; #78440), was added to each well containing
Matrigel and cells. After incubation at 37°C for 30 minutes, the cells
and gels were scraped from the plates, pipetted into 15-ml conical tubes,
and spun at 1200 rpm for 15 minutes at room temperature. The cell
pellets were lysed using the RNeasy Mini Kit (Qiagen, Valencia,
CA) as per the manufacturer’s protocols. RNA integrity was deter-
mined by electrophoresis on a 1% agarose gel (distilled water, 10×
3-(N -morpholino)propanesulfonic acid buffer, and 37% formalde-
hyde) following the manufacturer’s protocol (Ambion, Inc).
TIMP1 ELISA
Short hairpin RNA (shRNA) lentiviral particles, small molecule
inhibitors, or DMSO (vehicle control) was added to 3D PDCs cul-
tured in CPM. After 72 hours, the amount of TIMP1 protein in the
cell culture medium was determined using the Human TIMP1
ELISA Kit (RayBiotech, Norcross, GA; Catalogue No. ELH-TIMP1-
001) following the manufacturer’s instructions. In brief, aliquots of
the cell culture supernatant were diluted 100-fold with a proprietary
buffer containing animal serum and 0.09% sodium azide. A stan-
dard curve of human rTIMP1 protein was established as per the
manufacturer’s instructions. HRP-conjugated TIMP1-specific anti-
body from the ELISA kit was then added at a 100 μl volume (as per
the manufacturer’s instructions) to each well of a 96-well plate (in
three replicates) and incubated for 2.5 hours at room temperature.
The wells were washed four times with the proprietary wash solu-
tion. One hundred microliters of biotinylated antibody was added
to each well and incubated at room temperature for 1 hour. Next,
100 μl of a prepared streptavidin solution was added to each well and
incubated at room temperature for 1 hour with gentle shaking on a
laboratory shaker (Belly Dancer). Lastly, the chromogenic HRP sub-
strate 3,3′,5,5′-tetramethylbenzidine was added to each well. After
30 minutes, the reaction was stopped with 50 μl of sulfuric acid and
the plate was scanned at 480 nm in a Synergy BioTek4 microplate reader
(Winooski, VT). The mean absorbance of each set of triplicate standards,
controls, and samples was calculated and adjusted to the optical density
of the “zero/background control” standard. Protein concentration in each
sample was calculated from a best-fit line of a plot of absorbance versus
standard concentration.
Microarray Analysis
Focused human microarrays (SABiosciences, Valencia, CA; PAHS-
013Z) were processed and analyzed as previously described [7]. For
RNA isolation, the cell pellets were lysed using the Qiagen RNeasy
Mini Kit as per the manufacturer’s protocols. RNA integrity was deter-
mined by electrophoresis on a 1% agarose gel (distilled water, 10× 3-
(N -morpholino)propanesulfonic acid buffer, and 37% formaldehyde)
following the manufacturer’s protocol (Ambion, Inc). RNA concentra-
tion was determined using a NanoDrop 2000. To eliminate genomic
DNA contamination, 5 μg of RNA was first dissolved in 50 μl of the
Qiagen GE buffer and incubated at 42°C for 5 minutes. One micro-
gram of the purified RNA from each experimental condition was reverse
transcribed to cDNA using the Qiagen First Strand Kit reaction assay on
an EppendorfMastercycler Pro S (Hauppauge, NY). Next, 50 μl of a mix
Figure 2. E6/E7/Ras PDCs exhibit decreased proliferation after ERK2 inhibition. (A) K-RasG12D–mutated PDCs were cultured in 3D for
24 hours. Then, either DMSO, the MEK1/2 inhibitor UO126, or the ERK2-specific inhibitor AEMT was added for an additional 24 hours.
At that point, each well was pulse-labeled with a bromodeoxyuridine analog (EdU, green) for 6 hours as a marker of DNA synthesis and
cell proliferation. All nuclei were subsequently labeled (DAPI, blue). Images were observed at ×20 magnification. Scale bar, 100 μm.
(B) Inhibition of MEK1/2 and ERK2 by either UO126 or AEMT caused a significant decrease in the proliferation of the oncogenic PDCs after
quantifying EdU incorporation compared to total cell numbers (EdU/DAPI). Data are normalized to the proliferation of control untreated
cells and presented as means ± SEM. *P < .05, **P < .01. (C) K-RasG12D–mutated PDCs were infected with lentivirus harboring scram-
bled or shRNA constructs directed against ERK1 and ERK2 before 3D culture. The total ERK1 and ERK2 protein after RNA silencing was
determined by Western blot analysis and normalized to GAPDH loading control. Ratios reflect densitometric protein comparisons
between E6/E7/Ras infection with vehicle control, scramble, sh-ERK1, and sh-ERK2. For details, see Materials and Methods section.
(D) E6/E7/Ras PDCs were either left untreated (control) or transfected with scrambled, ERK1, or ERK2-specific sh- constructs and cultured
in 3D for 72 hours before proliferation analysis. A percentage of cell numbers compared to control E6/E7/Ras cells was calculated in
five different fields of view between three experiments. Data are presented as means ± SEM. *P < .05. (E) Phase contrast micrographs
of E6/E7/Ras PDCs treated as in D and cultured in both 2D (top panels) and 3D (bottom panels) for 72 hours before observation. Original
magnification, ×20. Scale bars, 50 μm.
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of reverse transcriptase buffer, primers, deoxynucleotide triphosphates
(dNTPs), and reverse transcriptase was added, incubated at 42°C
for 15 minutes, and heat inactivated at 95°C for 5 minutes. Finally,
455 μl of nuclease-free water was added for a total volume of 555 μl.
For each reaction, 5 μl of this cDNA was added to 20 μl of Qiagen
Mastermix and this cocktail was added to a 96-well SABiosciences
Extracellular Matrix Microarray Plate (PAHS-013Z; SABiosciences).
The cDNA plate was processed on an aluminum block Eppendorf
ep Realplex II calibrated with an SABiosciences “A” Plate using a
520 nm filter and a SYBRGreen probe. The polymerase chain reaction
(PCR) program entailed one heat activation cycle at 95°C followed
by 40 cycles of PCR (95°C × 15 seconds, 55°C × 15 seconds, 60°C ×
20 seconds) at a 35% ramp rate. Quantitative reverse transcription–
PCR (qRT-PCR) was followed by a melting curve analysis (95°C ×
15 seconds, 60°C × 15 seconds, at a 0.4°C heating rate with a final
inactivation at 95°C × 15 seconds) to verify purity by constant linear
dissociation over time. Bioinformatics analysis of the PCR data was
carried out using the Web-based RT2 Profiler PCR Array Data Ana-
lyzer (SABiosciences) after logarithmic transformation of C t amplifi-
cation values against internal controls, while the threshold was
consistently set by internal program controls. Data are expressed as
ΔΔC t as well as fold changes with ±2-fold considered as significant.
qPCR of Human Cells
Total RNA from both E6/E7 and E6/E7/Ras PDC lines was isolated
from 3D cultures using the Qiagen RNeasy Mini Kit and reverse tran-
scribed to cDNA as above. Real-time qPCR analysis of TIMP1 gene
expression was performed with the Applied Biosystems (Carlsbad,
CA) human TaqMan Gene Expression Assay (Hs00171558_m1) in
an Eppendorf Mastercycler ep Realplex II. For the PCR reaction, we
used the TaqMan Universal PCR Mastermix in a volume of 25 μl fol-
lowing the manufacturer’s protocol (Applied Biosystems) with glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH; Hs99999905_m1)
as an invariant housekeeping gene.
qPCR of Murine Cells
RNA from sorted magnetic-assisted cell sorting/fluorescence-
assisted cell sorting (MACS/FACS) murine cells was isolated using the
RNAqueous-Micro Kit (Ambion, Inc). One microgram of RNA was
primed using random hexamers and transcribed into cDNA (TaqMan
Reverse Transcription Reagents; Applied Biosystems, Branchburg, NJ).
SYBR Green was detected and quantitative analysis was performed on
the StepOnePlus System (Applied Biosystems, Branchburg, NJ).
Primer sequences for TIMP1 are given as follows: forward,
5′-CTCAAGACCTATAGTGCTGGC-3′; reverse, 5′-CAA-
AGTGACGGCTCTGGTAG-3′. P < .05 was statistically significant
(Mann-Whitney-Wilcoxon test). Error bars represent the SEM.
Gene Silencing
PDCs were plated on GFR Matrigel in a 24-well plate 24 hours
before viral infection at ∼25% confluence. Five hundred microliters
of CPM supplemented with 2% Matrigel was added to each well and
incubated overnight. The next day, the medium was aspirated and the
cells were refed with 400 μl of CPM. The cationic polymer, Polybrene,
was added to each well at 4 μg/ml to increase infection efficiency and
incubated for 4 hours (Sigma-Aldrich, St Louis, MO; AL-118). Pools of
three to five target-specific 19- to 25-nucleotide siRNA particles directed
against TIMP1 (Santa Cruz Biotechnology, Dallas, TX; 29505-V) and
copGFP control viral particles (Santa Cruz Biotechnology; 134220) were
added to 2D and 3D cultures of PDCs grown on GFR Matrigel at a
volume of 80 μl (approximately 1 × 105 infectious particles). The plates
were incubated overnight. The next day, 500 μl of fresh CPMwas added
to each well without Polybrene for another 24 hours. This medium was
collected and frozen for TIMP1 ELISA studies, while the cDNA Fastlane
Isolation Protocol (Qiagen; 215011) was followed to isolate the cellular
RNA for immediate PCR. The lysates were transferred to RNase-free
tubes and incubated at 75°C for 5 minutes before qRT-PCR as above.
Animal Procedures
All procedures were approved by the Institutional Animal Care
and Use Committee of the University of Pennsylvania (Protocol
No. 802868, No. 803699, and No. 804209). The Pdx1cre and
LSL-KrasG12D/+ mice were used for studies [26,27].
Statistical Analysis
Unless stated otherwise, all experiments were run in triplicate and
repeated independently at least three times. Where possible, the data
are expressed as averages ± SEM. Significance was based on P < .05
and P < .01 and clarified in each figure. Significance between two
data sets was determined using a two-tailed Student’s t test, while
differences between multiple experimental groups were determined
by two-way analysis of variance (ANOVA) with a Bonferroni post hoc
test. Microarray data sets were initially filtered for genes with more
than a two-fold change in ΔΔC t values. Internal microarray controls
were assessed across all samples for equal variance before comparison.
Significant increases in gene expression were determined by the Pffafl
method, which normalizes expression values to endogenous levels of
GAPDH to untreated control cells.
Results
Mutant K-RasG12D Increases Human PDC Proliferation
We previously demonstrated that an invasive phenotype in vitro is
only observed in K-RasG12D–mutated PDCs cultured in a 3D base-
ment membrane ECM [7]. We therefore hypothesized that 3D culture
will similarly reveal differences in the proliferative capacity of the iso-
genic, progressively transformed PDCs [18,20]. For these studies, we
used the defined set of primary human PDCs that incorporate a step-
wise retroviral transfection of human telomerase reverse transcriptase
(hTERT), the addition of human papillomavirus E6 and E7 proteins,
and a final glycine to aspartate mutation in the 12th position of K-Ras
that imparts transformative and epithelial-to-mesenchymal characteris-
tics (Figure 1A) [7].
The proliferative rates of cell cycle–deregulated E6/E7 and E6/E7/Ras
clones were indistinguishable in 2D despite the additional K-RasG12D
mutation (Figure W1). As expected following p53 and Rb/p16 inhibi-
tion by introduction of E6/E7, both clones (E6/E7 and E6/E7/Ras)
exhibited increased proliferation in 3D when compared to the hTERT
clone (Figure 1C ). Conversely, 3D culture could readily distinguish
between E6/E7 and E6/E7/Ras PDCs, in terms of their invasive mor-
phology (invadapodia, disorganized aggregation; Figure 1B ) and rates
of proliferation (Figure 1C ), although both of these parameters were
indistinguishable in 2D. The population doubling times of immor-
talized hTERT and E6/E7 PDCs in 3D were approximately 48 and
24 hours, respectively, while the doubling time of the K-RasG12D was
shortened to 12 hours (Figure 1C ; two-way ANOVA significance at
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Figure 3. TIMP1 is directly upregulated by the 3D K-RasG12D–ERK2 signaling axis. (A) Schematic detailing genetic/pharmacologic manip-
ulations of the cells used for subsequent microarray analyses. (B) Heat chart of gene expression signatures produced by unbiased hier-
archical clustering of PDCs under various conditions. Top blue boxes, E6/E7 PDCs; red boxes, E6/E7/Ras PDCs; yellow boxes, E6/E7/Ras
PDCs + 5 μMUO126; green boxes, E6/E7/Ras PDCs + 10 μMUO126. (C) Twelve genes with more than a two-fold change and regulated
specifically by the K-RasG12D–ERK2 axis were extracted from the gene signatures and distributed by relative increases in gene expression
after addition of K-RasG12D within the pie chart. (D) Volcano plot of 84 genes distributed by P value and fold change. Horizontal blue line
represents a significant P value threshold of .5 and induced by K-RasG12D. MMP1 and TIMP1 are labeled. (E) Volcano plot of the same
84 genes after K-RasG12D up-regulation of specific genes followed by ERK2 inhibition of a subset of this pool of genes by P value and fold
change. Those now significantly downregulated based on MAPKi alone are above the P value > .05 threshold. MMP1 and TIMP1 are
labeled. (F) Increasing concentrations of UO126 were added to 3D E6/E7/Ras cultures and RNAwas isolated for qRT-PCR analysis. MAPKi
significantly decreased TIMP1 expression in a dose-dependent manner. Data are presented as means ± SEM. *P < .05. No significance
between MAPKi concentrations.
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72 hours). The two non–K-RasG12D mutated clones (hTERT and E6/
E7) formed rounded non-invasive pancreatospheres composed of 3 to
15 individual cells within 48 hours (Figure 1B, right panels). Although
the organization of the pancreatospheres was similar between the hTERT
and E6/E7 PDC clones, the E6/E7 PDCs contained three to eight
more cells per aggregate, in line with their altered cell cycle deregulation
and increased proliferative potential (Figure 1D). Remarkably, addition
of a K-RasG12D mutation caused severe disruption of the rounded epi-
thelial morphology. Not only were rounded pancreatospheres no longer
recognizable, these invasive aggregates contained five times more cells
per aggregate and the cells appeared more flattened, elongated, and
mesenchymal-appearing in phenotype (Figure 1, B and D).
ERK2 Regulates Mutant K-RasG12D–Directed
PDC Proliferation
E6/E7/Ras PDC invasion is specifically regulated by the K-Ras–
MAPK/ERK2 pathway but only in 3D culture [7]. Therefore, we
tested the hypothesis that inhibition of this particular pathway is suf-
ficient to also significantly reduce PDC proliferation. MEK1/2 and
ERK2-specific small molecule inhibitors (UO126 and AEMT, respec-
tively) were added to E6/E7/Ras PDC 3D cultures and DNA synthesis
was assessed by EdU incorporation (Figure 2A, green fluorescence)
[28]. As seen in Figure 2B, MEK1/2 inhibition by UO126 reduced
the number of proliferating cells in the disorganized cell aggregates by
approximately 40%, while ERK2-specific inactivation by AEMT de-
creased the number of EdU-positive nuclei by an additional 10% (ap-
proximately 50% inhibition).
To further implicate ERK2 as the specific isoform controlling the
proliferation of mutated K-RasG12D cells, we infected PDCs with
shRNA lentiviral constructs capable of silencing ERK1 or ERK2,
respectively. After verifying >90% transfection efficiency by constitu-
tive green fluorescence protein (GFP) expression (data not shown),
we observed that total ERK1 or ERK2 protein expression was de-
creased for both constructs, respectively, by at least 75%, 48 hours
post-silencing (Figure 2C ). Subsequently, we cultured each silenced
clone in both 2D and 3D for another 24 hours (72 hours total post-
silencing) and measured proliferation by counting the total number
of cells. As seen in Figure 2D, proliferation of E6/E7/Ras PDCs in
3D was significantly reduced only upon silencing of ERK2 but not
ERK1. Additionally, both the number of invadapodia and number of
cells per aggregate were decreased in E6/E7/Ras PDCs, again only
when ERK2 was silenced, yielding cultures that were morphologically
reminiscent of E6/E7 and hTERT 3D pancreatospheres (Figures 1B
and 2E , bottom panels). The proliferation of K-RasG12D–mutated
PDCs cultured in 2D was also decreased with ERK2 silencing but
not with ERK1 silencing. The rate of proliferation of these sh-ERK2–
treated “transformed” cells was similar to that of the “normal” hTERT
clone (Figures 1B and 2E , top panels). These data indicate that the
K-RasG12D mutation increases the proliferation of PDCs through an
ERK2-specific MAPK pathway. Further, ERK2-specific antagonists,
both smallmolecule inhibitors andRNAi, will abolish the hyperprolifera-
tion induced by K-RasG12D and degenerate the invadapodia of mutated
PDCs, yielding more organized pancreatospheres in 3D.
TIMP1 Is Upregulated by the Constitutive K-Ras–ERK2
Signaling Axis
Because both invasion and cell proliferation appear regulated by the
K-RasG12D–ERK2 pathway in 3D culture, we next attempted to iden-
tify proliferation-related genes that were affected downstream of this
pathway. Using a focused microarray, we compared the expression
profiles of 84 ECM-related genes in 3D cultures of E6/E7 PDCs
and E6/E7/Ras PDCs in the presence of two different concentrations
of the MAPK inhibitor (MAPKi), UO126 to understand dose depen-
dent expression patterns (Figure 3A). Initially, we filtered the data
for those genes that were upregulated by more than two-fold in the
K-RasG12D–mutated cells (Figure 3B, cluster 1, top bar, red boxes).
Next, we identified genes of that filtered subset that were subsequently
downregulated by more than two-fold upon exposure to increasing
concentrations of the MAPKi (Figure 1B, cluster 1, top bar, yellow
(5 μM) and green (10 μM) boxes). Of the 84 genes analyzed, we iden-
tified 12 genes that were under the direct control of mutant K-RasG12D
through MAPK (Figure 3C and Table 1). For each of these 12 genes,
we calculated the ratio of expression levels (adjusted to the group’s over-
all sum) following the addition of K-RasG12D. The resulting data are
depicted in a pie chart where the gene’s relative share of the pie is
reflective of its K-RasG12D–induced log-fold change. All of these genes
have previously been implicated in human and mouse PDAC trans-
formation and metastasis [5,29,30]. Of the genes listed in Figure 3C ,
only the promoter for TIMP1 has published binding sites relevant
for transcription factors (e.g., PEA3, AP1, and Ets) that could relay
K-RasG12D–mutated signals through ERK2 in PDCs [11,12,20,31].
Comparison of significantly upregulated genes in E6/E7/Ras versus
E6/E7 PDCs by volcano plot analysis confirms significant gene up-
regulation of TIMP1 and, as previously published,MMP1, signifying
explicit control by the MAPK pathway (Figure 3D) [7]. More impor-
tantly, when the MAPK pathway was inhibited with either 5 or 10 μM
of UO126, the most significantly downregulated genes in the K-Ras–
mutated cells were againMMP1 and TIMP1, emphasizing that their
expression is under the direct influence of MAPK (Figure 3E). Vali-
dation of the array data by qPCR indicates that TIMP1mRNA expres-
sion is reduced when the K-RasG12D–ERK pathway is inhibited by
UO126 (Figure 3F ).
We subsequently used an ELISA-based assay to measure the concen-
tration of secreted TIMP1 protein under various 3D culture conditions
Table 1. Official Gene Name of Analyzed RNA for Each Gene Symbol.
Genes determined to be significantly changed after microarray analysis were set into this table to
coordinate each gene’s symbol with its official name.
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(Figure 4A). In line with the gene expression data, TIMP1 secretion
from E6/E7/Ras PDCs was approximately five-fold higher than that
from untransformed E6/E7 PDCs (∼12 pg/ml increased to ∼57 pg/ml)
after normalization of total cell protein lysates (Figure 4B). As expected
for a receptor tyrosine kinase–uncoupled GTPase, epidermal growth fac-
tor (EGF) addition had no statistically significant effect on TIMP1
expression in K-RasG12D PDCs. By contrast, inhibition of ERK1/2
phosphorylation by UO126 and sh-ERK2 (but not sh-ERK1) signifi-
cantly reduced TIMP1 secretion from E6/E7/Ras PDCs to levels
similar to those seen in the E6/E7 cell culture supernatants. Taken
together, these data suggest that the elevated TIMP1 expression at
the level of both gene and gene product is mediated specifically through
the K-RasG12D–MAPK–ERK2 axis.
TIMP1 Increases Proliferation of K-RasG12D–Mutated PDCs
TIMP1 has been shown to increase proliferation of epithelial and
stellate cells [20,32]. Recent evidence suggests that the proliferative
augmentation of TIMP1 can only be recognized in 3D cell culture
[18]. To establish TIMP1 as a functional modulator of aberrant pro-
liferation of PDCs harboring mutated K-RasG12D, we transduced
these cells with TIMP1-specific shRNA reducing TIMP1 expression
by ∼70% (Figure 4B). Paradoxically, neither 2D nor 3D culture of
TIMP1–silenced K-RasG12D PDCs showed a significant decrease in
cell numbers or a morphologic reversal to pancreatospheres, similar
to mammosphere assays (Figure 4, C and D) [18].
As increased TIMP1 expression is observed in fetal ductal morpho-
genesis and growth as well as during active epithelial proliferation of
pubertal mammary ducts, we hypothesized that TIMP1 may initiate
its growth promoting effects only at higher concentrations that are
found in deregulated, frank PDAC [33,34]. To determine the in vivo
TIMP1 RNA levels within a native pancreatic microenvironment, we
compared TIMP1 gene expression levels in mice with a K-RasG12D
mutation (Pdx1-Cre;LSL-KrasG12D/+) to appropriate Pdx1-Cre;Kras+/+
control mice. A majority of Pdx1-Cre;LSL-KrasG12D/+ mice develop
PanIN lesions between 10 and 20 weeks of age, while a subset develop
Figure 4. TIMP1 secretion is specifically regulated by ERK2 but is not necessary for basal proliferation. (A) E6/E7 and E6/E7/Ras PDCs
plus 10 ng/ml EGF, 10 μM UO126, or 80 μl of sh-ERK1 or sh-ERK2 lentiviral particles were cultured in 3D for 72 hours before analyzing
TIMP1 levels in aliquots of supernatant. Protein levels were quantified based on a TIMP1 standard curve. Data are presented as means
± SEM. **P< .01. (B) E6/E7/Ras PDCs were infected with five pooled lentiviral TIMP1 shRNA constructs and cultured in 3D for 72 hours.
RNA was isolated and qRT-PCR analysis determined a 70% reduction in TIMP1 transcript expression. Data are presented as means
± SEM. *P < .05. (C) Total number of E6/E7/Ras PDCs 72 hours post-TIMP1 silencing was determined in five fields of view between
three repeated experiments and compared to control. Data are presented as means ± SEM. NS, not significant. (D) No significant differ-
ences were observed in the cell morphology or total numbers of control E6/E7/Ras PDCs versus TIMP1 silenced. Images observed at
×40 magnification. Scale bars, 100 μm.
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PDAC [35]. PDCs were separated from all other cells in primary iso-
lates of mixed populations of pancreatic cells by ferromagnetic isolation
of DBA+ cells, which is specific for ductal structures including ADM
and PanIN lesions (Sox 9, Keratin19, HNF1β positive) [2]. RNA
purified from the DBA+ cell fraction of Pdx1-Cre;LSL-KrasG12D/+mice
contained 12-fold higher levels of TIMP1 when compared to control
animals (Figure 5).
Wedetermined that E6/E7/RasPDCs secreted approximately 57 pg/ml
TIMP1 protein over 72 hours by ELISA. This concentration of human
rTIMP1 protein was unable to significantly increase the proliferation of
neither E6/E7 nor E6/E7/Ras PDCs in 3D when added for 24, 48, or
72 hours (data not shown). This would indicate that independent levels
of E6/E7/Ras-secreted TIMP1 is not sufficient to induce proliferation
and that additional exogenous sources added by the non-ductal com-
partment may be necessary to observe effects on ductal cells. In an effort
to mimic the increased in vivo RNA and protein levels of TIMP1 in
both the ductal and non-ductal compartments, a minimal three-fold
increased concentration (∼200 pg/ml) was added to both E6/E7 and
E6/E7/Ras PDCs in 3D for 24, 48, and 72 hours. As seen in Figure 6A,
addition of this concentration of rTIMP1 promoted significant prolif-
eration ofK-RasG12D–mutated PDCs (especially pronounced at 72 hours)
but did not result in a statically significant increase in the cell numbers
in the untransformed E6/E7 PDCs.
To further define the influence of K-RasG12D mutations on TIMP1
secretion and proliferation, we performed rescue experiments using
shRNA directed against TIMP1 mRNA with or without the addition
of exogenous rTIMP1 and determined cell proliferation by assessing the
number of EdU-positive cells (Figure 6B). As seen in the quantitative
Figure 5. TIMP1 is significantly increased in primary pancreatic cells isolated from K-RasG12D–mutated mouse and in sera from human
PDAC patients. (A) Graphic representation of the process for pancreatic ductal cell sorting (ductal vs non-ductal compartments) from
Pdx1-Cre;LSL-KrasG12D/+ and Pdx1-Cre;Kras+/+ control mice before RNA analysis. For details, see Materials and Methods section. (B) Graph
showing relative mTIMP1 expressed in the primary DBA+ ductal epithelial cells isolated from KrasG12D+ mice compared to that of wild-type
mice. Data are presented as means of triplicates ± SEM. (C) The Oncomine public database was mined for TIMP1 gene up-regulation in
six separate RNA microarray analyses over the last decade of multiple human samples of pancreatic cancer, specifically ductal adeno-
carcinoma.Multivariate analysis of the data sets confirms that the TIMP1 gene is significantly increased in human pancreatic cancer samples
with a P value < .000173. Oncomine (Compendia Bioscience, Ann Arbor, MI) was used for analysis and visualization.
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evaluation of these micrographs, addition of sh-TIMP1 had no ob-
servable effect on E6/E7/RasDNA synthesis compared to vehicle con-
trol, which was contrary to the addition of either a MEK or ERK2
inhibitor (Figure 6C ). However, the addition of rTIMP1 after
TIMP1 silencing caused a small but statistically significant increase
in DNA synthesis. Importantly, the addition of human rTIMP1 to
vehicle-only K-RasG12D–mutated PDCs caused a robust increase in
DNA synthesis, underscoring TIMP1’s ability to induce prolifera-
tion over basal levels only at pathologically higher concentrations
(Figure 6C ).
Discussion
Here, we provide evidence that a K-RasG12D mutation activates
ERK2-specific signaling that increases TIMP1 expression and secretion
from an isogenic series of human PDCs, an increase also readily seen
in primary pancreatic cells directly processed in vivo from K-RasG12D–
mutated mice. This induction of TIMP1 sufficiently provokes aber-
rant hyperplasia in our human PDC culture model but only in the
K-RasG12D–mutated cells cultured in 3D. Importantly, normal MAPK
signaling dynamics must be shifted toward constitutively activated
MEK-ERK2 for hyperproliferation to occur [36–38]. Recent evidence
suggests that this MAPK signaling pathway can only be recapitulated
in epithelial cells embedded in a 3D ECM matrix, providing a more
“in vivo-like” aggregate architecture [7,18,39,40].
When compared to the immortalized parental hTERTPDCs, increased
proliferation of both E6/E7 and E6/E7/Ras cells is to be expected due
to the inactivation of p53/Rb and p16INK4a by the human papilloma-
virus proteins E6 and E7, a fact readily seen even in 2D [23]. Despite
a deregulated cell cycle, E6/E7 PDCs still attach to laminin through
integrin α6 and organize into “pancreatospheres” with a center void
of cells, similar to hTERT PDCs [7]. It is only with the addition of
Figure 6. Exogenous TIMP1 induces E6/E7/Ras proliferation. (A) E6/E7 and E6/E7/Ras PDCs were cultured in 3D for 24 hours and then
were cultured in the presence of either DMSO (vehicle) or human rTIMP1 and analyzed at 24, 48, and 72 hours. Data (average cell
numbers/field of view) are presented as means ± SEM. *P < .05, **P < .01. (B) Control E6/E7/Ras PDCs with and without sh-TIMP1
and/or rTIMP1 were cultured in 3D for 72 hours before EdU (green) pulse labeling for 6 hours. Cultures were fixed and nuclei were
labeled with DAPI (blue) before analysis. Images at ×4 magnification. Scale bars, 100 μm. (C) The number of proliferating E6/E7/Ras
PDCs in the presence of the MEK/ERK2 inhibitors UO126 and AEMT, sh-TIMP1, sh-TIMP1 plus rTIMP1, and control plus rTIMP1 were
quantified. By normalizing the nuclei labeled with EdU to the total number of DAPI-stained nuclei, the percent proliferating under each
experimental condition, normalized to the proliferation of non-treated control cells, was assessed. Data are presented as means ± SEM.
*P < .05, **P < .01.
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a K-RasG12Dmutation and only in 3D culture that an invasive phenotype
results in the characteristic invadapodia of epithelial-to-mesenchymal
transition [7,18]. In extending our previous findings, we now report
that only K-RasG12D–mutated PDCs 1) increase TIMP1 secretion both
in vitro and in vivo and 2) exhibit significant hyperproliferation and
non-ductal architecture in 3D when exposed to high concentrations
of exogenous TIMP1. These observations suggest that constitutive
K-RasG12D signaling leads to the up-regulation of a variety of down-
stream genes that stimulate both invasion and hyperproliferation in
an ERK2-dependent manner (Figure 2).
K-Ras regulates cell cycle progression as well as proliferative gene
expression through the MAPK pathway [7,41,42]. DNA synthesis
(as defined by EdU incorporation) and total cell counts in 3D cul-
tured E6/E7/Ras PDCs were greatly diminished after MAPK inhibi-
tion with either UO126 (having an affinity for MEK1 over MEK2 at
5–10 μM) or the ERK2-specific inhibitor (AEMT; Figure 2). Pref-
erential MEK1 inhibition prohibits accumulation of ERK2 in the
nucleus, thereby inhibiting proliferation [43]. AEMT permits
ERK2 phosphorylation by MEK but abolishes its downstream kinase
activity, thereby inhibiting activation of ERK2-specific proliferation-
associated genes [28]. This specific feature of phosphorylated ERK2
is only apparent in 3D cultured E6/E7/Ras PDCs and its activity
positively correlates with enhanced cell proliferation (Figures 1 and
2). As in vivo data suggest that ERK1 overexpression inhibits Ras-
induced subcutaneous tumor proliferation in nude mice, it follows
that ERK2 overexpression may be a more favorable driver of Ras-
regulated proliferation as we have shown in our mutated pancreatic
cells [7,28,38]. In support of this notion, silencing of ERK2, and not
ERK1, reduces E6/E7/Ras PDC hyperproliferation by approximately
65% in 3D (Figure 2). Although ERK1 and ERK2 share both primary
RNA sequence and tertiary protein structure, ERK2’s hinge region is
modulated differently than ERK1 allowing different interdomain inter-
actions [44]. Interestingly, when cultured in 2D, ERK2-silenced
E6/E7/Ras PDCs exhibit a similar rate of proliferation as hTERT-
transfected “normal” PDCs (Figure 2). As E6 and E7 proteins readily
upregulate upstream MAPK pathway signaling in addition to onco-
genic Ras, it follows that ERK2 pathway inhibition either reverses
the unrestrained cell cycle progression caused by p53/Rb and p16INK4a
inactivation in PDCs or that it directs the K-Ras–MAPK signaling
pathway toward ERK1 away from ERK2 proliferation induction [38].
It is important to note that while we have shown increased DNA syn-
thesis due to the K-RasG12D mutation here in PDCs, increased cell sur-
vival due to AKT can also contribute to the total cell mass of neoplasms
[45]. By targeting uniquely ERK2-dependent transformation capacities
in addition to AKT, novel MAPK isoform-specific inhibitors that could
bypass toxicity induced by the less selective inhibition of upstream effec-
tor molecules (i.e., B-Raf and MEK) while reducing the overall tumor
burden might be developed [7,39,44,46].
Having discovered a constitutive K-RasG12D–driven, ERK2-mediated
hyperproliferation axis, we used the gene signature of E6/E7 PDCs as a
“non-transformed” baseline. This threshold distinguished downstream
gene expression changes due to only the K-RasG12D mutation in E6/
E7/Ras PDCs and pinpointed specific genes that were directly regulated
byMEK-ERK2 (Figure 3). Unbiased hierarchical analysis of our micro-
array data identified 12 K-RasG12D–ERK2–regulated genes that were as-
sociated with potential epithelial-to-mesenchymal transition, ECM
molecules, and proteases. Of those genes with proliferation-inducing
potential, we focused on TIMP1 and validated its enhanced expression
by qPCR. Indeed, analysis of tissue biopsy data in the Oncomine data-
base confirms that TIMP1 is consistently overexpressed by at least two-
fold inmultiple data sets of PDACpatients with a significantP value of at
least .0002 (Figure 5C ). Further, TIMP1 is increased within the sera
of pancreatic cancer patients, both of which implicate involvement in
proliferation and biomarker potentiality [47,48].
Although originally named for its ability to inhibit MMPs, TIMP1 is
a dual function molecule theorized to be capable of growth-promoting
activities at its C terminus, independent of its N-terminal endopepti-
dase inhibition characteristic [49]. Interestingly, TIMP1 has gene
sequence homology to erythropoietin and has been shown to induce
growth in a variety of cell types including breast, skin, and liver cells
[18,20,50]. Although the concentrations of TIMP1 found in vivo are
less than necessary to promote erythropoietin-like JAK2 proliferative
signaling, TIMP1 may still retain the ability to promote proliferation
through cellular membrane binding [18,21]. Indeed, prior studies dem-
onstrate that high TIMP1 expression can induce in vivo tumor growth
and alter the abundance of its MMP1 target depending on the dimen-
sionality of the model [7,18,51]. Analysis of the MMP1 and TIMP1
promoter gene sequences reveals that both share putative consensus
binding sites for a number of ERK-regulated transcription factors.
Adjacent AP1, PEA3, and Ets regions 180 bp upstream of these gene
expression sites may be involved in simultaneous transcriptional activa-
tion [12,31,41]. Thus, if ERK2 were to activate various transcription
factors such as early growth response or ets transactivation variance,
these factors could have a greater tendency to transcribe MMP1 and
TIMP1, thus providing potential pretranscriptional and intertran-
scriptional targets for pharmacological inhibition of invasion and
proliferation [7,52].
In accordance with ERK2-activated transcription of the TIMP1
gene, ELISA revealed increased TIMP1 protein secretion in PDCs
harboring a K-RasG12D mutation (Figure 4). Importantly, addition of
exogenous EGF did not further increase TIMP1 secretion, presumably
due to the tyrosine kinase–independent activity of constitutive K-RasG12D
signaling [4]. Pharmacological and RNAi inhibition of ERK2, but not
ERK1, reduced the secretion of TIMP1, underscoring its regulation by this
particular ERK isoform.Whether ERK2 silencing decreases both transcript
and protein abundance or instead prevents extracellular TIMP1 secre-
tion through an alternate mechanism has yet to be determined. TIMP1-
silenced E6/E7/Ras PDCs exhibited minimal changes in 3D morphology
or proliferation when compared to non-silenced controls similar to previ-
ous studies, underscoring that K-RasG12D must sufficiently induce higher
microenvironment TIMP1 concentrations to yield increased proliferation
(Figure 4) [31,53].
Indeed, primary cells isolated from the ductal pancreatic compart-
ment of Pdx1-Cre;LSL-KrasG12D/+ mice express approximately 12-fold
higher levels of TIMP1 RNA than control cells from “normal” mice
(Figure 5). As others have found that the majority of TIMP1 is derived
from the ductal compartment and secreted into the extracellular milieu,
it is logical that its expression increased in the DBA+ PDC fraction of
KrasG12D/+ mice pancreata [10]. Paralleling this finding and that ele-
vated TIMP1 levels are found in clinical patients’ sera, a minimal three-
fold addition of human rTIMP1 increased EdU incorporation into
the nuclei of PDCs cultured in 3D but, again, only if they harbored a
K-RasG12D mutation (Figure 6) [47,48]. This observation suggests
that 1) the proliferative effect of TIMP1 overexpression requires an
active K-RasG12D mutation in PDCs and cannot induce proliferative
signaling otherwise and 2) the addition of non-ductal derived and
secreted TIMP1 is necessary to raise the microenvironment concen-
tration over a non-proliferative threshold. As overexpression but not
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silencing had an appreciable effect on cell proliferation, we surmise that
TIMP1 may initiate its growth factor–like activity only at concentra-
tions high enough to saturate its primary MMP inhibitory abilities,
shifting the MMP-TIMP balance and enhancing extracellular mem-
brane binding [9,54]. Interestingly, addition of exogenous rTIMP1
did not affect the proliferation of E6/E7 PDCs, which harbor an intact
EGF receptor–dependent K-Ras signaling axis. As mutated K-RasG12D
PDCs are independent of EGF receptor activation, these observations
suggest that TIMP1 is exerting its proliferative effects by activating
either a yet to be identified K-RasG12D upregulated receptor tyrosine
kinase molecule or other putative cellular targets, such as hepatocyte
growth factor or the CD63 receptor [50,55].
In non-transformed cells, TIMP1 inhibits cellular proliferation
due to its repression of Wnt/β-catenin signaling; this inhibitory effect
seems to be suppressed in transformed cells harboring K-Rasmutations
because mutant K-Ras constitutively stimulates Wnt signaling and
stabilizes β-catenin [54,56,57]. Further, although in vivo TIMP1 over-
expression has been found to reduce the proliferation of pancreatic
cancer cells injected within a murine peritoneum, decreased prolifera-
tion is only observed when TIMP1 is measured acutely [58]. When
TIMP1 is overexpressed 24 hours after pancreatic cancer cell intro-
duction, it actually increases the disseminated tumor volume, in line
with our primary murine and human PDC 3D models (at 72 hours).
These studies may explain why TIMP1 is capable of initiating prolifer-
ation in only K-RasG12D PDCs and only in 3D: TIMP1 harbors a pro-
tumorigenic effect after K-RasG12D–mutated PDCs have established
unrestricted mechanical associations with the 3D ECM [7].
We conclude that K-RasG12D PDCs overexpress TIMP1 through
an ERK2 signaling axis in a 3D ECM environment. The resulting
increase in TIMP1 protein secretion leads to hyperproliferation of
only K-RasG12D–mutated PDCs. Implicitly and as a caveat, therapeutic
utilization of exogenous TIMP1 to reduceMMP-directed metastases in
K-RasG12D–mutated pancreatic cancer may invariably stimulate prolif-
eration of PDCs.
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Figure W1. Human pancreatic cells harboring E6 and E7 increase
pancreatic cell proliferation. Total cell numbers for each individual
clone was quantified after 72 hours in 2D culture at 6- or 12-hour
intervals. At each time point, cell total was determined as the
average count of five individual fields of three separate cultures
of each individual clone. Data are presented as means ± SEM.
*P < .05.
